Best Grants for Cancer Nonprofits in Arizona

The NCI Pathway to Independence Award (K99/R00) aims to support talented postdoctoral researchers in their transition to independent faculty positions. This program provides essential NCI research funding to help awardees establish competitive, independent research careers. Applications must be submitted by 5:00 PM local time of the applicant's organization, ensuring timely consideration for this critical funding opportunity.

The ASTRO-LUNGevity Residents/Fellows in Radiation Oncology Seed Grant aims to enhance the research careers of residents and fellows focused on radiation oncology, specifically benefiting lung cancer patients. This initiative supports basic, translational, and clinical research endeavors. With a maximum award amount of $50,000 for one year, it provides essential funding to foster innovative projects that can lead to significant advancements in lung cancer treatment.

The Postdoctoral Grant Program at the University of Wisconsin School of Medicine and Public Health aims to support the growth and professional development of postdoctoral trainees, fellows, and associates. With funding up to $20,000 for one year, recipients can engage in independent research projects, attend workshops, or cover open-access publication fees. This initiative enhances research capacity and promotes health equity in Wisconsin, addressing critical health challenges while fostering career advancement in the medical field.

The Cancer Center Support Grants (CCSGs) aim to bolster NCI-Designated Cancer Centers through funding that supports diverse research activities. These grants enhance comprehensive, clinical, and basic cancer research while fostering collaboration among institutions. The program prioritizes interdisciplinary approaches to advance cancer prevention, diagnosis, and treatment, ultimately reducing cancer's impact on public health. CCSGs also facilitate resource sharing, administrative support, and the development of innovative research initiatives.

The ASTRO-AstraZeneca SCLC Therapy Challenge RFP aims to enhance research on limited-stage small cell lung cancer (LS-SCLC) through innovative combination therapies, particularly integrating immunotherapy with advanced radiation techniques. Proposals are encouraged to explore various aspects, including care patterns, treatment workflows, prognostic biomarkers, and toxicity management. The target budget for projects ranges from $175,000 to $375,000, with consideration given to higher requests based on scientific merit, fostering significant advancements in radiation oncology.

This Notice of Funding Opportunity (NOFO) is one of three NOFOs for the National Cancer Institute (NCI) Community Oncology Research Program (NCORP). NCORP is designed to enhance generalizability and dissemination of clinical trial results through accrual in a variety of community settings. The purpose of NCORP is to engage cancer patient populations, those at risk of cancer, and organizations in rigorous studies focused on cancer control, prevention, treatment and care delivery.NCORP will support the following components that will be individually awarded through the respective RFAs indicated below:

• NCORP Research Bases (UG1 Clinical Trials Required);
• NCORP Community Sites (UG1 Clinical Trials Not Allowed); and
• NCORP Academic Community Sites (UG1 Clinical Trials Not Allowed)

NCORP Community Sites are consortia of community hospitals and/or oncology practices, which may or may not be formally affiliated in a healthcare system, that accrues participants to cancer control, prevention, treatment and care delivery clinical trials and other human subjects research.

This Notice of Funding Opportunity (NOFO) is one of three NOFOs for the National Cancer Institute (NCI) Community Oncology Research Program (NCORP). NCORP is designed to enhance generalizability and dissemination of clinical trial results through accrual in a variety of community settings. The purpose of NCORP is to engage cancer patient populations, those at risk of cancer, and organizations in rigorous studies focused on cancer control, prevention, treatment and care delivery. NCORP will support the following components that will be individually awarded through the respective Request for Applications (RFAs) indicated below:

• NCORP Research Bases (UG1 Clinical Trials Required);
• NCORP Community Sites (UG1 Clinical Trials Not Allowed); and
• NCORP Academic Community Sites (UG1 Clinical Trials Not Allowed)

The RFA: Biology to Prevention Award (CRUK) aims to foster innovative translational research that enhances understanding of cancer biology, ultimately leading to effective prevention strategies. Joint applications from UK and US research teams are encouraged, with a focus on equal partnerships and complementary expertise. The funding provides up to £600,000 for UK costs and up to $946,000 for US costs, supporting projects of 1 to 5 years duration that address critical research questions in cancer prevention.

The Anna Fuller Fund Grant provides year-round support for organizations dedicated to alleviating suffering caused by cancer. Established in memory of Egbert C. Fuller’s wife, the fund prioritizes applications that focus on cancer research and education initiatives. Eligible applicants must be 501(c)(3) organizations or equivalent charities outside the U.S. Grant funds cannot be used for direct treatment, ensuring that resources are allocated to research and public education.

The James Paul Sutton Medical Research Fund Grant supports non-profit organizations engaged in cancer and medical research, established through a trust by the Sutton family. Eligible organizations must be 501(c)(3) exempt. Preference is given to cancer research initiatives, while grants are not available for individuals, political groups, or for-profit entities. This fund aims to sustain medical research efforts for the long term, continuing the legacy of the Sutton family.

The National Cancer Institute (NCI) plans to issue a Notice of Funding Opportunity (NOFO) for the Paul Calabresi Career Development Award in Clinical Oncology (K12). This program aims to enhance training for clinician-scientists in cancer research, fostering their career development and collaboration with basic research scientists. It mandates diverse oncology specialties in faculty, individualized career development plans, and mentorship, supporting Scholars for up to three years to promote their research initiatives in clinical trials.

The Simeon J. Fortin Charitable Foundation, founded in 1986, champions cancer research initiatives aimed at finding a cure. It supports relevant projects and fellowships within medical and research institutions, ensuring a significant impact on health-related research. The grant review process is conducted by The Medical Foundation, in coordination with the King Trust Postdoctoral Fellowships, enhancing collaboration and funding opportunities for innovative research in oncology.

The AGD Foundation Grant Program supports nonprofit organizations in the U.S. and Canada that provide free oral cancer screenings and education, particularly for underserved communities. Established in 1972, the AGD Foundation aims to enhance public oral health and raise awareness about oral/oropharyngeal cancer. By promoting early detection and education, the foundation seeks to improve survival rates and empower communities. Eligible applicants must be 501(c)(3) organizations demonstrating a commitment to community health.

The grant program by Pfizer, Inc. aims to enhance the knowledge of Advanced Practice Providers (APPs) in the field of biomarker and genetic testing for cancer. By providing educational resources and programs, this initiative seeks to empower APPs to make informed treatment decisions in oncology, ultimately improving patient outcomes. This program encourages applications that address the specific educational needs of APPs, particularly in using biomarkers for targeted therapies.

Arizona cancer and oncology organizations educating healthcare professionals on metastatic prostate cancer and PARP-inhibitor combination treatments can access funding through Pfizer. This competitive grant supports independent research, quality improvement, or educational projects that address biomarker and genetic testing, PARPi safety and efficacy, multidisciplinary care, and best practices for community-based guideline-concordant treatment.

Individuals being treated for Waldenstrom macroglobulinemia in Arizona can apply for HealthWell Foundation’s Waldenstrom Macroglobulinemia Fund; awards up to US $8,000 for prescription drug copays and Medicare Part B insurance premiums. Patients must be underinsured, receiving treatment in the U.S., have qualifying insurance, and meet income guidelines tied to the Federal Poverty Level.

Cancer researchers at U.S. academic institutions or eligible nonprofits, including those in Arizona, can seek more than US $135,000 from the American Cancer Society and Fanconi Cancer Foundation for high-risk, high-reward translational projects. Funding supports innovative work to improve detection, prevention, or treatment of cancers in individuals with Fanconi anemia.

Individuals being treated for mantle cell lymphoma in Arizona can receive help with prescription drug copays and Medicare Part B premiums through this fund. Grants from Healthwell Foundation help U.S. patients with insurance and incomes within 300–500% of the Federal Poverty Level cover treatment-related out-of-pocket costs, with awards up to US $8,500.

Underinsured U.S. patients being treated for chronic lymphocytic leukemia can receive up to US $8,000 to cover prescription drug copays and Medicare Part B insurance premiums. With a mission to reduce financial barriers to care, Healthwell Foundation provides nationwide cancer and leukemia patients with support for high-cost medications listed under this disease-specific fund.

Individuals being treated for cancer-related behavioral health conditions in Arizona and across the U.S. can receive up to US $2,000 to offset prescription copays, counseling, psychotherapy, and related transportation costs. The Healthwell Foundation supports underinsured patients whose income and insurance status meet its guidelines, helping reduce financial barriers to essential behavioral health care.

Underinsured patients being treated for amyloidosis in the U.S., including Arizona, can receive up to US $8,000 to cover prescription drug copays and Medicare Part B premiums. The Healthwell Foundation supports individuals whose insurance covers part of their cancer-related medications and whose household income falls within its federal poverty level guidelines.

The NCI Research Specialist Award (R50) supports clinician scientists involved in NCI-funded clinical trials. This funding opportunity encourages the development of stable research careers by providing salary support and autonomy, allowing clinician scientists to contribute to national clinical trial development and implementation. They play a critical role in sustaining the NCI clinical trials network without serving as principal investigators. This award aims to ensure continuity in cancer research careers.

The NCI Research Specialist Award (R50) supports non-tenure track scientists in cancer research who provide essential contributions within laboratories and core facilities. This award aims to enhance research careers for skilled scientists who do not seek independent investigator funding. Eligible candidates must possess an advanced degree, have at least two years of contribution to NCI-funded research, and dedicate a significant portion of their time to this work. The R50 offers salary support and travel funds to recognize and stabilize these vital roles in cancer research.

Improving Metastatic Prostate Cancer (mPCa) Care Through Innovative Strategies

The National Comprehensive Cancer Network® and Pfizer Global Medical Grants (Pfizer) are collaborating to offer a new grant opportunity seeking proposals for investigator-initiated research to improve mPCa care. Pfizer (hereafter, “Grantor”) is providing $1 Million in funding to support quality improvement studies to advance health care quality, the delivery of quality care, and improve health care provider performance in mPCa care. The Grantor will serve as the funding organization. Grants are available to all investigators from institutions within the United States. 

Aim

To promote the advancement of scientific knowledge, health care provider performance, and/or health care quality improvement focused on improving mPCa care.

A total of $1 Million is available to fund all projects. The intent is to fund 2-5 studies. There is a funding cap of $250,000 per study. Exceptional studies with budgets above this amount will be considered based on scientific merit and must contain a robust justification. All budgets must include line-item information and robust justification.

The Radiation Oncology-Biology Integration Network (ROBIN) Centers, funded by the National Cancer Institute (NCI), aims to enhance national radiation oncology infrastructure through collaborative research. This initiative supports studies on biological responses to radiation treatment in cancer patients, focusing on understanding tumor and tissue changes. By integrating various scientific disciplines and collecting comprehensive data, ROBIN intends to improve cancer care, optimize treatment strategies, and accelerate translational discoveries to enhance patient outcomes.

The Paul Calabresi Career Development Award for Clinical Oncology aims to enhance the training of clinician-scientists in clinical and translational cancer research. This funding opportunity encourages the career growth of researchers but does not permit Scholars to lead independent clinical trials. Instead, it allows participation in clinical trials under the mentorship of an experienced researcher, fostering a collaborative approach to cancer research.

The DoW Rare Cancers Concept Award for FY26 promotes groundbreaking ideas in rare cancer research. This award encourages innovative applications that explore novel courses of investigation without requiring preliminary data. Unique to this program is the prohibition against mentioning the Principal Investigator or collaborators in the proposal materials, ensuring an unbiased review process. This funding opportunity aims to advance scientific discovery in the rare cancer domain.